ResMed Inc. (NYSE:RMD) agreed to acquire Medifox-Dan Dresden Gmbh for €950 million on June 14, 2022. Transaction will be financed through ResMed's existing credit facilities. Transaction is subject to regulatory clearances and expected to close by the end of the second quarter of ResMed's fiscal year 2023. For the year ended 2021, Medifox had revenues of approximately $83 million and EBITDA of approximately $35 million. Evercore Inc. acted as financial advisor and DLA Piper LLP (US) acted as legal advisor to ResMed Inc. Poellath acted as legal advisor to Medifox